Cost-Effectiveness of Psilocybin-Assisted Therapy vs. Standard of Care for Patients With Treatment-Resistant Depression
Author(s)
Yosr ziadi, MSc, Dr. Taehwan Park, Associate Professor.
Pharmacy Administration and Public Health, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY, USA.
Pharmacy Administration and Public Health, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY, USA.
OBJECTIVES: Patients with treatment-resistant depression (TRD) experience high relapse rates and a relentless cycle of ineffective treatments, significantly impairing their quality of life and burdening healthcare resources. Psilocybin has emerged as a promising alternative, offering rapid and sustained symptom relief. However, its cost-effectiveness remains unexplored. This study conducted a pioneering cost-effectiveness analysis of psilocybin-assisted therapy (PAT) versus standard care (SoC) for individuals with TRD using a Markov model from a U.S. healthcare perspective.
METHODS: The model, parameterized by randomized trial efficacy data and a micro-costing approach, simulated patient transitions every six-week cycle, consistent with American Psychiatric Association guidelines. Outcomes focused on response/remission rates and incremental cost-effectiveness ratios (ICERs), expressed in 2023 U.S. dollars per quality-adjusted life years (QALYs). Extensive deterministic and probabilistic sensitivity analyses (PSA) explored uncertainties. Dosing and price point variations were also examined in scenario analysis to identify optimal strategies.
RESULTS: Psilocybin consistently dominated SoC, providing cost savings (ΔCosts = -$7,037) and superior clinical benefits (ΔQALY = 0.10). PAT increased remission by 3.20% and response by 7.75%, gaining between 0.15 and 0.25 QALYs. The PSA demonstrated an 81.98% likelihood of PAT being optimal at a $50,000/QALY threshold, with 65.89% of iterations showing greater effectiveness at lower costs. Notably, the Incremental Net Monetary Benefit (INMB) analysis indicated a value of $12,765 at this threshold, reinforcing PAT's cost-effectiveness. No scenario identified SoC as more cost-effective. PAT retained its superiority across all willingness-to-pay (WTP) values (from $50,000 to $200,000) and remained the optimal strategy across all price levels evaluated (from $500 to $10,000). Scenario analysis revealed that administering two doses three weeks apart was the most cost-effective regimen.
CONCLUSIONS: Psilocybin offers a groundbreaking, cost-effective alternative to SoC for TRD. These findings support its integration into treatment protocols, warrant further research into its long-term benefits, and position PAT as a promising strategy for future clinical guidelines.
METHODS: The model, parameterized by randomized trial efficacy data and a micro-costing approach, simulated patient transitions every six-week cycle, consistent with American Psychiatric Association guidelines. Outcomes focused on response/remission rates and incremental cost-effectiveness ratios (ICERs), expressed in 2023 U.S. dollars per quality-adjusted life years (QALYs). Extensive deterministic and probabilistic sensitivity analyses (PSA) explored uncertainties. Dosing and price point variations were also examined in scenario analysis to identify optimal strategies.
RESULTS: Psilocybin consistently dominated SoC, providing cost savings (ΔCosts = -$7,037) and superior clinical benefits (ΔQALY = 0.10). PAT increased remission by 3.20% and response by 7.75%, gaining between 0.15 and 0.25 QALYs. The PSA demonstrated an 81.98% likelihood of PAT being optimal at a $50,000/QALY threshold, with 65.89% of iterations showing greater effectiveness at lower costs. Notably, the Incremental Net Monetary Benefit (INMB) analysis indicated a value of $12,765 at this threshold, reinforcing PAT's cost-effectiveness. No scenario identified SoC as more cost-effective. PAT retained its superiority across all willingness-to-pay (WTP) values (from $50,000 to $200,000) and remained the optimal strategy across all price levels evaluated (from $500 to $10,000). Scenario analysis revealed that administering two doses three weeks apart was the most cost-effective regimen.
CONCLUSIONS: Psilocybin offers a groundbreaking, cost-effective alternative to SoC for TRD. These findings support its integration into treatment protocols, warrant further research into its long-term benefits, and position PAT as a promising strategy for future clinical guidelines.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE270
Topic
Economic Evaluation
Topic Subcategory
Thresholds & Opportunity Cost
Disease
Mental Health (including addition), No Additional Disease & Conditions/Specialized Treatment Areas